AI and Value-Based Care: Machine Learning’s Potential in Reducing Healthcare Waste

By Michael Awood

October 8, 2023

According to a new study, the United States wastes $1 trillion a year on healthcare. The staggering cost of inefficiency is higher than the world’s 17th-biggest country’s GDP. Waste in healthcare affects patient care, the speed of organisations, and the cost of materials. Mistakes and wasteful spending are more likely in the healthcare system due to its complexity. This severely reduces the effectiveness of treatment.

Value-based care methods were created to deal with this issue. They promote cost-effective clinical results that lead to high-quality care at a fair price. In a data-rich environment, making decisions can become too complicated. These things cause mistakes, which make it harder to get high-value care, which wastes more time and money.

Putting this in perspective, about 80,000 people die every year in the US because of inaccurate outcomes. Even with the most up-to-date training and tools, healthcare still has problems. Maintaining awareness of the growing amount of medical info requires a lot of mental effort.

With the help of Machine Learning, both the number of mistakes and the amount of resources used could go down. Algorithms can now be used to make diagnoses instead of the human equivalent, i.e: radiologists, pathologists, and doctors. By using automations such as event reporting, you can keep patients safe. Putting together local, real-time data from institutions and social media could help with public health management and change how we predict future epidemics.

ML might be able to make personalised treatment plans for each patient based on genetic information, clinical presentation factors, and information about the patient’s past. This means that patients get more personalised care, go through fewer therapies that are unsuccessful, and have better overall outcomes.

But these changes also bring about new problems. Problems exist with both the quality of the data and our ability to understand the data that machines create. Accountability for mistakes and bad outcomes, as well as protecting patients’ privacy, are challenging.

Rising healthcare costs not only hurt countries in significant amounts, but they also threaten the foundations of value-based medicine. When it comes to keeping our healthcare system safe, ML shows itself to be a strong tool with immense potential. While there isn’t a guaranteed way to make healthcare better without also making it more efficient, ML shows promise in this area.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.